TY - JOUR
T1 - TeleHealth resistance exercise intervention to preserve dose intensity and vitality in elder breast Cancer patients (THRIVE 65)
AU - Schmitz, Kathryn H.
AU - Berger, Nathan A.
AU - Owusu, Cynthia
AU - Thomson, Cynthia A.
AU - Chinchilli, Vernon M.
AU - Basen-Engquist, Karen
AU - Evans, William J.
AU - Pink, John J.
AU - Schleicher, Erica A.
AU - Cao, Chao
AU - Doerksen, Shawna E.
AU - Binder, Jenna D.
AU - Sobolewski, Michele D.
AU - Tanasijevic, Anna M.
AU - Diguglielmo, Kaedryn A.
AU - Nguyen, Truong L.
AU - Mills, Carissa A.
AU - Kemp, Wendy
AU - Oppenheim, Jay B.
AU - Ligibel, Jennifer A.
N1 - Publisher Copyright:
© 2025
PY - 2025/11
Y1 - 2025/11
N2 - Background: Older women with breast cancer are more likely than younger women to experience dose-limiting toxicities with chemotherapy. This leads to dose reduction, treatment discontinuation, and inferior treatment outcomes. Older women are also at higher risk of long-term detrimental impacts of treatment on quality of life and physical function. Aim: The primary aim of the TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE-65) trial is to assess the effects of an exercise and nutrition intervention on chemotherapy relative dose intensity among women aged ≥65 receiving chemotherapy for early-stage breast cancer. Methods/Design: THRIVE-65 is a 2-arm parallel-group randomized controlled trial. The intervention includes two 30–45 min telehealth delivered resistance exercise sessions weekly, 90 min of unsupervised aerobic exercise weekly, and dietitian-guided high protein intake (1.2 g/kg/day)) delivered throughout the course of chemotherapy. The Health Education and Support control group receives a tablet with supportive care materials. Planned and observed chemotherapy dose and treatment schedule are recorded to assess relative dose intensity. Pre- and post- intervention assessments include patient reported outcomes, a geriatric assessment, dietary and physical activity measures, physical function and body composition. Conclusions: The THRIVE-65 trial is poised to answer a crucial scientific question: Can exercise and nutrition support improve chemotherapy tolerance among older breast cancer patients? Study results will inform clinical practice related to exercise and nutrition support for this population.
AB - Background: Older women with breast cancer are more likely than younger women to experience dose-limiting toxicities with chemotherapy. This leads to dose reduction, treatment discontinuation, and inferior treatment outcomes. Older women are also at higher risk of long-term detrimental impacts of treatment on quality of life and physical function. Aim: The primary aim of the TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE-65) trial is to assess the effects of an exercise and nutrition intervention on chemotherapy relative dose intensity among women aged ≥65 receiving chemotherapy for early-stage breast cancer. Methods/Design: THRIVE-65 is a 2-arm parallel-group randomized controlled trial. The intervention includes two 30–45 min telehealth delivered resistance exercise sessions weekly, 90 min of unsupervised aerobic exercise weekly, and dietitian-guided high protein intake (1.2 g/kg/day)) delivered throughout the course of chemotherapy. The Health Education and Support control group receives a tablet with supportive care materials. Planned and observed chemotherapy dose and treatment schedule are recorded to assess relative dose intensity. Pre- and post- intervention assessments include patient reported outcomes, a geriatric assessment, dietary and physical activity measures, physical function and body composition. Conclusions: The THRIVE-65 trial is poised to answer a crucial scientific question: Can exercise and nutrition support improve chemotherapy tolerance among older breast cancer patients? Study results will inform clinical practice related to exercise and nutrition support for this population.
KW - Breast cancer
KW - Exercise
KW - Nutrition
KW - Relative dose intensity
UR - https://www.scopus.com/pages/publications/105016195951
UR - https://www.scopus.com/pages/publications/105016195951#tab=citedBy
U2 - 10.1016/j.cct.2025.108074
DO - 10.1016/j.cct.2025.108074
M3 - Article
C2 - 40947050
AN - SCOPUS:105016195951
SN - 1551-7144
VL - 158
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 108074
ER -